OCX - Oncocyte Corporation
0 0%
Share volume: 0
Last Updated:
Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances:
-0.08%
PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
View ratios
| Fiscal Date | 03-31-2025 | |
|---|---|---|
| Fiscal Quarter | Q1 2025 | |
| Report Date | 05-12-2025 | |
| Total revenue | 2.138 M | |
| Cost of revenue | 813.000 K | |
| Gross profit | 1.325 M | |
| Operating expenses | 6.039 M | |
| Selling general and admin | 3.115 M | |
| Research and development | 2.924 M | |
| Total expenses | 8.124 M | |
| Operating income | -6.799 M | |
| Ebit | -6.642 M | |
| Pretax income | -6.671 M | |
| Income tax | 0.000 | |
| Net income basic | 0.000 | |
| Net income | -6.671 M | |